Core Viewpoint - The global gene sequencing industry is undergoing a competitive restructuring, prompting the company to optimize its global business layout and business model [1] Group 1: Business Transactions - The company announced the sale of 100% equity of its wholly-owned subsidiary CGI to Swiss Rockets for approximately $50 million, following the separation of related assets and liabilities [2] - The company has revised the previously signed CoolMPS sequencing technology licensing agreement to include exclusive licensing of StandardMPS sequencing technology, enhancing strategic collaboration with Swiss Rockets [2][3] - The transaction is seen as a key move for the company to replace "asset outflow" with "technology outflow" in a complex international environment [2] Group 2: Financial Implications - The company expects to receive at least $120 million in revenue from the new licensing agreement, which includes a $20 million upfront payment, a $20 million milestone payment, and tiered royalties based on net sales [4] - The transaction is anticipated to bring significant direct benefits and improve cash flow, as the company will receive approximately $50 million from the equity transfer and reduce losses from the underperforming CGI business unit [4] - The shift from high-volatility direct overseas operations to a structured, predictable revenue model is expected to enhance financial resilience [4] Group 3: Strategic Reorientation - The company has permanently and irrevocably licensed back 205 patents from CGI, ensuring the integrity of its technology system and business continuity for future global licensing [5] - The company will continue to lead the expansion of CoolMPS in the Asia-Pacific and Greater China regions while promoting StandardMPS globally outside the U.S. and Canada [5] - The move to transfer North American operations to a partner is a proactive adaptation to the current geopolitical and regulatory environment, allowing the company to maintain technology output and market penetration [6] Group 4: Industry Context - Swiss Rockets, established in 2018, focuses on innovative biopharmaceuticals and has rapidly expanded its asset scale, providing support for the collaboration [6] - The company is also enhancing its technology integration by acquiring 100% equity of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd., incorporating core capabilities in spatiotemporal omics and nanopore sequencing [6]